Examining blood cell growth patterns and heart health in Hodgkin lymphoma survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the relationship between blood cell growth patterns, known as therapy-related clonal hematopoiesis (t-CH), and cardiovascular health in patients who have undergone treatment for Hodgkin lymphoma. The study aims to identify the prevalence of somatic mutations associated with cardiovascular disease (CVD) in these patients and assess their heart health using cardiac magnetic resonance imaging (MRI). By understanding these patterns, the study seeks to identify individuals at higher risk for heart complications, allowing for closer monitoring and early intervention. Participants will provide blood samples, complete surveys, and undergo cardiac MRI, while their medical records will be reviewed for comprehensive analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient must be \>= 7 years of age at the time of enrollment (age to perform an MRI without sedation).
* History of pathologically confirmed classical Hodgkin Lymphoma (cHL) initially diagnosed when the patient was \>= 2 and \< 22 years of age.
* As part of frontline therapy for cHL, the patient must have received a cumulative doxorubicin equivalent anthracycline dose of ≥ 200 mg/m\^2 as estimated in doxorubicin isotoxic equivalents dose conversion calculation.

  * Note: History of COG therapeutic trial participation is not required. Institutional records (e.g., clinic note, treatment summary, chemotherapy roadmap) can be used as reference documentation of receipt of anthracycline dose.
* All systemic cancer treatment must have been completed ≥ 2 years prior to study enrollment.
* Not known to have had a primary event (relapse/second malignancy/death).

  * Note: Subjects treated at another institution are eligible if they are now being followed at the current COG institution, if the study procedures can be performed and the data accessible by a COG institution where the study is open.
* Patient must have access to cardiac MRI at the enrolling institution and must be able to complete cardiac MRI without sedation.

Exclusion Criteria:

* Medical contraindication to undergoing a non-contrast cardiac MRI.
* Patients with nodular lymphocyte-predominant HL.
* Received cancer therapy in addition to that for primary Hodgkin Disease (e.g., for disease progression or recurrence, or subsequent malignant neoplasm).
* History of CTCAE grade 3 or higher cardiovascular disease or condition known to exist prior to the patient's initial diagnosis of cHL.

  * Note: exceptions are made for congenital conditions considered fully resolved by surgery and chronic conditions such as hypertension or hypercholesterolemia that are managed with medical intervention.
* History of an immunodeficiency that existed prior to cHL diagnosis, such as primary immunodeficiency syndromes, organ transplant recipients and conditions requiring systemic immunosuppressive agents.

Where it's running

• USA Health Strada Patient Care Center
  Mobile, Alabama, United States Recruiting
• Phoenix Childrens Hospital
  Phoenix, Arizona, United States Recruiting
• City of Hope Comprehensive Cancer Center
  Duarte, California, United States Recruiting
• Valley Children's Hospital
  Madera, California, United States Recruiting
• Connecticut Children's Medical Center
  Hartford, Connecticut, United States Recruiting
• Yale University
  New Haven, Connecticut, United States Recruiting

Study contacts

• Principal investigator: Robert J Hayashi — Children's Oncology Group

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-Fiber Plant-Based Diet in People with Clonal Hematopoiesis

  This study tests whether a high-fiber plant-based diet can improve quality of life for adults with clonal hematopoiesis.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07590804

• Bone density changes with anti-PD-1 immunotherapy

  This pilot will test if anti-PD-1 immunotherapy changes bone density in adults starting approved anti-PD-1 treatment for certain early-stage cancers.

  Recruiting Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07555210

• Clonal haematopoiesis assessment and long-term monitoring for prevention and care

  This project will follow people aged 55 and older who have clonal haematopoiesis or unexplained low blood counts to see how their blood changes over time and whether they develop heart disease or blood cancers.

  Recruiting Clinical Hub for Interventional Research (CHOIR) · Canberra, Australian Capital Territory · NCT07313059

• Pembrolizumab plus chemotherapy for frail adults with classical Hodgkin lymphoma who can't get standard treatment

  This phase II trial tests whether adding pembrolizumab to gemcitabine-based chemotherapy (with possible brentuximab vedotin and dacarbazine) helps frail adults newly diagnosed with classical Hodgkin lymphoma who are ineligible for standard anthracycline-based therapy.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07275216

• ctDNA-guided therapy for relapsed or refractory Hodgkin lymphoma using pembrolizumab with GVD

  This study tests a pembrolizumab-based regimen plus chemotherapy in adults with relapsed or refractory classic Hodgkin lymphoma to see if ctDNA can guide treatment response and consolidation choices.

  Recruiting Phase 2 University of California, San Francisco · Davis, California and 5 other locations · NCT07021989

• Personalized chemotherapy reduction for advanced Hodgkin lymphoma

  This study is testing if people with advanced Hodgkin lymphoma can safely get fewer rounds of personalized chemotherapy based on their tumor DNA levels while still effectively treating their cancer.

  Recruiting at 6 sites Phase 2 University of Washington · Irvine, California and 5 other locations · NCT06745076

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.